intestinal microbiota in copd and asthma

Conditions: Chronic Respiratory Diseases

Summary: the composition of the intestinal microbiota, the level of lipopolysaccharides, tmao in the blood, and other parameters of patients with copd (n=50), asthma (n=50) and the control (n=40) will be assessed as factors associated with exacerbations and respiratory symptoms in the prospective study (12 months).

the patients from "biobank of blood and feces for the development of a clinical and biological platform as a basis for an innovative approach to the prevention of chronic non-infectious diseases based on the composition of the intestinal microbiota" study will be included (cross-sectional study). the protocol of the above study included the assessment of socio-demographic, anthropometric data, clinical blood pressure (bp), ecg, blood tests, fecal microbiota studies, spirometry data, diet questionnaire. abpm, hbp, other questionnaires (mmrc, cat, acq-5, gmbq) will be added to initial data (=visit 1). than the four visits (2-5th visits) in 3 each months will be performed to assess respiratory symptoms, exacerbations of copd/asthma, respiratory infections, therapy, bp, and other parameters. the standard statistical methods will be used.

Eligibility criteria:
inclusion criteria: for control group: * normal spirometry results with bronchodilation test (salbutamol 400 mcg); * absence of copd, asthma, chronic bronchitis and other lung diseases * bmi\<40kg/m2 for asthma/copd groups: * primary medical documentation confirming the diagnosis of copd or asthma * regular therapy for copd, asthma and any chronic disease for at least 4 weeks prior to enrollment in this study. * fev1 / fvc \<0.70 after inhalation of 400 mcg of salbutamol for patients with copd * bmi\<40kg/m2 exclusion criteria: * exacerbation of chronic noninfectious diseases, including exacerbation of copd / asthma, within 4 weeks prior to enrollment in this study. * exacerbation of copd or asthma in the next 3 months, requiring the treatment of antibiotic therapy or systemic corticosteroids; * cerebral stroke, transient ischemic attack or myocardial infarction within 6 months before the date of enrollment in the study; * clinically significant chronic diseases (oncological, systemic diseases of the connective tissue, diseases of the blood system, heart failure, crohn's disease, ulcerative colitis, etc. according to anamnesis); * gfr \<30 ml / min / 1.73m2; * atopy in a patient with copd or a control group (any allergic manifestations - skin, nasal, conjunctival, food, etc.); * chronic respiratory diseases in a patient of the control group (copd, asthma, chronic bronchitis, interstitial lung diseases); * history of organ transplantation; * mental illness; * intestinal infection (food poisoning) in the next 3 months; * other acute infectious diseases. it is possible to turn on not earlier than 4 weeks after complete recovery and cessation of treatment; * history of severe covid-19; * hiv infection, chronic viral hepatitis according to the history; * clinically significant oncological disease; * pregnancy and lactation; * alcoholism, taking narcotic drugs; * taking antimicrobial, probiotic drugs and systemic corticosteroids during the last 3 months; * genetic engineering / biological therapy.

Keywords: intestinal microbiota copd asthma lipopolysaccharides trimethylamine-n-oxide course of the diseases exacerbation